1. Home
  2. Our Firm
  3. News
  4. Important update from Guggenheim about the "Heartbleed" virus

Our Firm

April 17, 2014

Important update from Guggenheim about the "Heartbleed" virus

What is Heartbleed?

You may have read about the "Heartbleed" security flaw that has exposed many websites to attackers. Heartbleed was discovered in OpenSSL, the data encryption standard used by a majority of websites around the world to transmit information securely. It lets attackers steal confidential data without being noticed, including passwords, bank account information, stored files, and Social Security numbers.

What should I do?

Guggenheim web properties are safe and do not use OpenSSL that Heartbleed affects so there is no need to change your usernames or passwords.



November 09, 2020

Guggenheim Securities Hires David Levin to Expand Equity Capital Markets

NEW YORK, NY –  Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that David Levin will join the firm as a Senior Managing Director in Equity Capital Markets, focusing on providing clients with equity and equity-linked financing solutions through the public and alternative equity capital markets.

Read More

October 22, 2020

Guggenheim Securities Hires Joe Niemiec to Expand Middle Market Investment Banking Practice

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Joe Niemiec has joined the firm as a Senior Managing Director to expand its middle market investment banking coverage and to focus on advising companies in the services and industrials sectors.

Read More

October 05, 2020

Debjit Chattopadhyay Joins Guggenheim Securities as Senior Biotech Analyst

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Debjit Chattopadhyay will join the firm in December as a Managing Director and Senior Biotech Analyst as part of the Healthcare Equity Research team. Dr. Chattopadhyay’s research focus will be gene therapy and rare diseases.

Read More



© 2020 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.